Ir para o conteúdo principal

Painreform Ltd (NASDAQ: PRFX) — Perfil da empresa, notícias e dados financeiros

Logo de Painreform Ltd
PRFX Painreform Ltd
Painreform Ltd primary media
Perfil da empresa

Painreform Ltd

Painreform (NASDAQ:PRFX) is committed to the development of innovative pain management solutions, with a focus on addressing post-operative pain through extended release drug applications. Currently, the company's projects include the formulation of drugs designed to provide prolonged pain relief, potentially reducing the need for opioids and improving patient outcomes after surgery. Painreform aims to revolutionize post-operative care by advancing these products through clinical trials and eventually bringing them to market for the benefit of patients worldwide. Their objective is not only to alleviate pain effectively but also to contribute to the fight against the opioid crisis by offering safer, non-addictive pain management alternatives.

Resumo

Public USParticipação acionária
2007Ano de fundação
7Funcionários
Herzliya, IsraelSede
Carregando mapa...
Presença global

Operações

Todos os locais
State of Israel

Produtos e/ou serviços de Painreform Ltd

  • PRF-110 is their lead product, an extended-release local anesthetic for post-surgical pain, offering potentially longer pain relief.
  • Development of proprietary technology for extended-release drug delivery, enhancing post-operative pain management.
  • Research into new formulations for existing drugs, aimed at improving efficacy and reducing side effects.
  • Collaboration with pharmaceutical companies for the co-development of new pain relief solutions.
  • Exploration into non-opioid pain management options to address the opioid crisis.
  • Advancement of patient-specific pain management protocols, utilizing their drug delivery technology for tailored treatments.

equipe executiva do Painreform Ltd

  • Ehud GellerExecutive Chairman
  • Eyal BroderChief Financial Officer
  • Sigal Aviel eMBAChief Operating Officer
  • Efraim Cohen-AraziInterim CEO & Director
  • Rita KeynanVice President of Pharmaceutical Operations

Principais indicadores financeiros

Resultados divulgados pela Painreform Ltd, em USD.

Cap. de mercado
2,7 mi
Receita (TTM)
31 mil
P/L
—
LPA (diluído, TTM)
-4.1
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Painreform Ltd
Fim do ano fiscalReceitaResultado operacionalLucro líquido
17 mil-5 mi-4,8 mi
0-14,7 mi-14,6 mi
0-9,6 mi-9,3 mi
86 mil-8,9 mi-8,8 mi